Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts

Seungyoun Jung¹, Naomi Allen², Alan A Arslan^{3

4}, Laura Baglietto^{5

6}, Aurelio Barricarte^{7

8

9}, Louise A Brinton¹⁰, Brian L Egleston¹¹, Roni T Falk¹⁰, Renée T Fortner¹², Kathy J Helzlsouer^{13

14}, Yutang Gao¹⁵, Annika Idahl¹⁶, Rudolph Kaaks¹², Vittorio Krogh¹⁷, Melissa A Merritt¹⁸, Eva Lundin¹⁹, N Charlotte Onland-Moret²⁰, Sabina Rinaldi²¹, Helena Schock¹², Xiao-Ou Shu²², Patrick M Sluss²³, Paul N Staats²⁴, Carlotta Sacerdote²⁵, Ruth C Travis²⁶, Anne Tjønneland²⁷, Antonia Trichopoulou^{28

29}, Shelley S Tworoger^{30

31}, Kala Visvanathan¹⁴, Elisabete Weiderpass^{32

33

34

35}, Anne Zeleniuch-Jacquotte⁴, Joanne F Dorgan¹

Affiliations

¹ Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD.
² Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
³ Department of Obstetrics and Gynecology, New York University School of Medicine, New York, NY.
⁴ Departments of Population Health and Environmental Medicine and Perlmutter Cancer Center, New York University School of Medicine, New York, NY.
⁵ Cancer Epidemiology Centre, Cancer Council of Victoria, Melbourne, Australia.
⁶ Centre for Epidemiology and Biostatistics, School of Population and Global Health, University of Melbourne, Melbourne, Australia.
⁷ Navarra Public Health Institute, Pamplona, Spain.
⁸ Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
⁹ CIBER Epidemiology and Public Health CIBERESP, Madrid, Spain.
¹⁰ Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
¹¹ Fox Chase Cancer Center, Philadelphia, PA.
¹² Division of Cancer Epidemiology, German Cancer Research Cancer, Heidelberg, Germany.
¹³ Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD.
¹⁴ Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
¹⁵ Department of Epidemiology, Shanghai Cancer Institute, Shanghai, China.
¹⁶ Department of Clinical Sciences, Obstetrics and Gynecology, Umeå University, Umeå, Sweden.
¹⁷ Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
¹⁸ Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom.
¹⁹ Department of Medical Biosciences, Pathology, and Public Health and Clinical Medicine: Nutritional Research, Umeå University, Umeå, Sweden.
²⁰ Department of Epidemiology, UMC Utrecht Julius Center, Uretcht, The Netherlands.
²¹ International Agency for Research on Cancer, Lyon, France.
²² Department of Epidemiology, Vanderbilt University School of Medicine, Nashville, TN.
²³ Department of Pathology, Harvard Medical School, Boston, MA.
²⁴ Department of Pathology, University of Maryland School of Medicine, Baltimore, MD.
²⁵ Unit of Cancer Epidemiology, Città della Salute e della Scienza University-Hospital and Center for Cancer Prevention (CPO), Turin, Italy.
²⁶ Cancer Epidemiology Unit, University of Oxford, Oxford, United Kingdom.
²⁷ Danish Cancer Society Research Center, Copenhagen, Denmark.
²⁸ Hellenic Health Foundation, Athens, Greece.
²⁹ WHO Collaborating Center for Nutrition and Health, Unit of Nutritional Epidemiology and Nutrition in Public Health, Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Athens, Greece.
³⁰ Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA.
³¹ Channing Division of Network Medicine, Bringham and Women's Hospital and Harvard Medical School, Boston, MA.
³² Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway.
³³ Department of Research, Cancer Registry of Norway, Institute of Population-Based Cancer Research, Oslo, Norway.
³⁴ Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
³⁵ Genetic Epidemiology Group, Folkhälsan Research Center, Helsinki, Finland.

PMID: 28921520
PMCID: PMC5749630
DOI: 10.1002/ijc.31058

Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts

Seungyoun Jung et al. Int J Cancer. 2018.

. 2018 Jan 15;142(2):262-270.

doi: 10.1002/ijc.31058. Epub 2017 Oct 4.

Authors

Affiliations

¹ Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD.
² Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
³ Department of Obstetrics and Gynecology, New York University School of Medicine, New York, NY.
⁴ Departments of Population Health and Environmental Medicine and Perlmutter Cancer Center, New York University School of Medicine, New York, NY.
⁵ Cancer Epidemiology Centre, Cancer Council of Victoria, Melbourne, Australia.
⁶ Centre for Epidemiology and Biostatistics, School of Population and Global Health, University of Melbourne, Melbourne, Australia.
⁷ Navarra Public Health Institute, Pamplona, Spain.
⁸ Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
⁹ CIBER Epidemiology and Public Health CIBERESP, Madrid, Spain.
¹⁰ Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
¹¹ Fox Chase Cancer Center, Philadelphia, PA.
¹² Division of Cancer Epidemiology, German Cancer Research Cancer, Heidelberg, Germany.
¹³ Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD.
¹⁴ Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
¹⁵ Department of Epidemiology, Shanghai Cancer Institute, Shanghai, China.
¹⁶ Department of Clinical Sciences, Obstetrics and Gynecology, Umeå University, Umeå, Sweden.
¹⁷ Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
¹⁸ Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom.
¹⁹ Department of Medical Biosciences, Pathology, and Public Health and Clinical Medicine: Nutritional Research, Umeå University, Umeå, Sweden.
²⁰ Department of Epidemiology, UMC Utrecht Julius Center, Uretcht, The Netherlands.
²¹ International Agency for Research on Cancer, Lyon, France.
²² Department of Epidemiology, Vanderbilt University School of Medicine, Nashville, TN.
²³ Department of Pathology, Harvard Medical School, Boston, MA.
²⁴ Department of Pathology, University of Maryland School of Medicine, Baltimore, MD.
²⁵ Unit of Cancer Epidemiology, Città della Salute e della Scienza University-Hospital and Center for Cancer Prevention (CPO), Turin, Italy.
²⁶ Cancer Epidemiology Unit, University of Oxford, Oxford, United Kingdom.
²⁷ Danish Cancer Society Research Center, Copenhagen, Denmark.
²⁸ Hellenic Health Foundation, Athens, Greece.
²⁹ WHO Collaborating Center for Nutrition and Health, Unit of Nutritional Epidemiology and Nutrition in Public Health, Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Athens, Greece.
³⁰ Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA.
³¹ Channing Division of Network Medicine, Bringham and Women's Hospital and Harvard Medical School, Boston, MA.
³² Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway.
³³ Department of Research, Cancer Registry of Norway, Institute of Population-Based Cancer Research, Oslo, Norway.
³⁴ Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
³⁵ Genetic Epidemiology Group, Folkhälsan Research Center, Helsinki, Finland.

PMID: 28921520
PMCID: PMC5749630
DOI: 10.1002/ijc.31058

Abstract

Animal and experimental data suggest that anti-Müllerian hormone (AMH) serves as a marker of ovarian reserve and inhibits the growth of ovarian tumors. However, few epidemiologic studies have examined the association between AMH and ovarian cancer risk. We conducted a nested case-control study of 302 ovarian cancer cases and 336 matched controls from nine cohorts. Prediagnostic blood samples of premenopausal women were assayed for AMH using a picoAMH enzyme-linked immunosorbent assay. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using multivariable-adjusted conditional logistic regression. AMH concentration was not associated with overall ovarian cancer risk. The multivariable-adjusted OR (95% CI), comparing the highest to the lowest quartile of AMH, was 0.99 (0.59-1.67) (P_trend : 0.91). The association did not differ by age at blood draw or oral contraceptive use (all P_{heterogeneity} : ≥0.26). There also was no evidence for heterogeneity of risk for tumors defined by histologic developmental pathway, stage, and grade, and by age at diagnosis and time between blood draw and diagnosis (all P_{heterogeneity} : ≥0.39). In conclusion, this analysis of mostly late premenopausal women from nine cohorts does not support the hypothesized inverse association between prediagnostic circulating levels of AMH and risk of ovarian cancer.

Keywords: anti-Müllerian hormone; epidemiology; ovarian cancer; ovarian function.

PubMed Disclaimer

Cited by

Environmental Exposures and Anti-Müllerian Hormone: A Mixture Analysis in the Nurses' Health Study II.
Li H, Hart JE, Mahalingaiah S, Nethery RC, James P, Bertone-Johnson E, Eliassen AH, Laden F. Li H, et al. Epidemiology. 2023 Jan 1;34(1):150-161. doi: 10.1097/EDE.0000000000001547. Epub 2022 Sep 22. Epidemiology. 2023. PMID: 36455251 Free PMC article.
Epigenetic and proteomic signatures associate with clonal hematopoiesis expansion rate.
Mack TM, Raddatz MA, Pershad Y, Nachun DC, Taylor KD, Guo X, Shuldiner AR, O'Connell JR, Kenny EE, Loos RJF, Redline S, Cade BE, Psaty BM, Bis JC, Brody JA, Silverman EK, Yun JH, Cho MH, DeMeo DL, Levy D, Johnson AD, Mathias RA, Yanek LR, Heckbert SR, Smith NL, Wiggins KL, Raffield LM, Carson AP, Rotter JI, Rich SS, Manichaikul AW, Gu CC, Chen YI, Lee WJ, Shoemaker MB, Roden DM, Kooperberg C, Auer PL, Desai P, Blackwell TW, Smith AV, Reiner AP, Jaiswal S, Weinstock JS, Bick AG. Mack TM, et al. Nat Aging. 2024 Aug;4(8):1043-1052. doi: 10.1038/s43587-024-00647-7. Epub 2024 Jun 4. Nat Aging. 2024. PMID: 38834882 Free PMC article.
Association of Anti-Mullerian Hormone, Follicle-Stimulating Hormone, and Inhibin B with Risk of Ovarian Cancer in the Janus Serum Bank.
Irvin SR, Weiderpass E, Stanczyk FZ, Brinton LA, Trabert B, Langseth H, Wentzensen N. Irvin SR, et al. Cancer Epidemiol Biomarkers Prev. 2020 Mar;29(3):636-642. doi: 10.1158/1055-9965.EPI-19-0675. Epub 2020 Jan 13. Cancer Epidemiol Biomarkers Prev. 2020. PMID: 31932414 Free PMC article.

References

1. Durlinger AL, Visser JA, Themmen AP. Regulation of ovarian function: the role of anti-Mullerian hormone. Reproduction (Cambridge, England) 2002;124:601–9. - PubMed
1. Visser JA, de Jong FH, Laven JS, Themmen AP. Anti-Mullerian hormone: a new marker for ovarian function. Reproduction (Cambridge, England) 2006;131:1–9. - PubMed
1. MacLaughlin DT, Donahoe PK. Mullerian inhibiting substance/anti-Mullerian hormone: a potential therapeutic agent for human ovarian and other cancers. Future oncology (London, England) 2010;6:391–405. - PMC - PubMed
1. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocrine reviews. 2001;22:255–88. - PubMed
1. Chin TW, Parry RL, Donahoe PK. Human mullerian inhibiting substance inhibits tumor growth in vitro and in vivo. Cancer research. 1991;51:2101–6. - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts

Affiliations

Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts

Authors

Affiliations

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical